Virus-Like Particles

Expression of influenza viral structural proteins, such as hemagglutinin (HA), neuraminidase and others, can result in the synthesis of virus-like particles (VLPs). The VLPs resemble viruses but contain no viral genome and therefore are safe “by design” as vaccines. 

Recombinant VLPs represent highly immunogenic and effective vaccines due to the natural epitopes that elicit efficient immunity. Medigen is using VLP technology to develop broadly protective influenza vaccines.